Praveen, I agree. Further, the improvement in weight gain is not broken out, so I gather it is not dramatic. Also, the comparison against haloperidol is not as good, and it's generic. Will the faster onset of action (also not broken out) and (probably) minor improvement in weight be enough to convince insurers to pay a lot more? I have my doubts. The stock is looking strong today again, and I am looking to exit my Mom's position on this strength. I also have doubts about 104, and as you say, PIII for 103 is a ways away.
Edit: Over 2.5 million shares short, heh, heh. This is one where they deserve to be roasted. A few days ago, that yielded a short ratio of 15+, but with the volume we're seeing, they could have covered (for large losses unless their timing was good on entry (i.e. when Cramer was pumping it)) by now.
Cheers, Tuck |
